Guided Therapeutics (GTHP) Income from Continuing Operations (2010 - 2026)
Guided Therapeutics (GTHP) posted Income from Continuing Operations of 1218000.0 for Q4 2025, down 64.15% sequentially from 742000.0 in Q3 2025, and down 86.81% YoY from 9234139.53 in Q4 2024.
Guided Therapeutics (GTHP) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Guided Therapeutics has reported Income from Continuing Operations for 16 years, with the latest figure at 1218000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 86.81% year-over-year to 1218000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3198000.0 (down 32.31% YoY) and the FY2025 annual result came in at 3196000.0, down 32.23% from the prior year.
- Income from Continuing Operations fell to 1218000.0 in Q4 2025 per GTHP's latest filing, from 742000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 68000.0 in Q3 2021 and troughed at 1807000.0 in Q4 2022.
- A 5-year average of 768650.0 and a median of 693000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations jumped 84.68% in 2021, then slumped 1720.59% in 2022.
- Over 5 years, Income from Continuing Operations stood at 444000.0 in 2021, then slumped by 306.98% to 1807000.0 in 2022, then jumped by 78.64% to 386000.0 in 2023, then slumped by 68.91% to 652000.0 in 2024, then plunged by 86.81% to 1218000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1218000.0, 742000.0, and 811000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | -605,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -605,000.00 |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -811,000.00 |
| Mar 31, 2025 | -427,000.00 |
| Dec 31, 2024 | -652,000.00 |
| Sep 30, 2024 | -654,000.00 |
| Jun 30, 2024 | -709,000.00 |
| Mar 31, 2024 | -402,000.00 |
| Dec 31, 2023 | -386,000.00 |
| Sep 30, 2023 | -677,000.00 |
| Jun 30, 2023 | -1.56 Mn |
| Mar 31, 2023 | -869,000.00 |
| Dec 31, 2022 | -1.81 Mn |
| Sep 30, 2022 | -1.10 Mn |
| Jun 30, 2022 | -926,000.00 |
| Mar 31, 2022 | -507,000.00 |
| Dec 31, 2021 | -444,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | -1.03 Mn |